Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1801

1.

[The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].

Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.

Rev Esp Cardiol. 2006 Jun;59(6):537-44. Spanish.

2.

Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.

Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ.

J Am Coll Cardiol. 1999 May;33(6):1596-601.

3.

Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L.

Pacing Clin Electrophysiol. 2003 Sep;26(9):1887-96.

PMID:
12930505
4.

Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.

Przybylski A, Małecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Ruzyłło W, Szwed H.

Kardiol Pol. 2005 Oct;63(4):391-7; discussion 398. English, Polish.

PMID:
16273479
5.

Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.

JAMA. 2007 Jul 25;298(4):405-12. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
17652294
6.

Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.

Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, Abecasis M, Neves JP, Bonhosrst D, Gomes JL, Gomes RS.

Rev Port Cardiol. 2005 Mar;24(3):407-15. English, Portuguese.

PMID:
15929624
7.

Hypertrophic cardiomyopathy: the importance of arrhythmic events in patients at risk for sudden cardiac death.

Medeiros Pde T, Martinelli Filho M, Arteaga E, Costa R, Siqueira S, Mady C, Piegas LS, Ramires JA.

Arq Bras Cardiol. 2006 Nov;87(5):649-57. English, Portuguese.

8.

Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.

Cuoco FA, Spencer WH 3rd, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, Leman RB, Wharton JM, Gold MR.

J Am Coll Cardiol. 2008 Nov 18;52(21):1718-23. doi: 10.1016/j.jacc.2008.07.061.

9.

Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.

Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA 3rd, Spirito P.

N Engl J Med. 2000 Feb 10;342(6):365-73.

10.

Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.

Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.

J Cardiovasc Electrophysiol. 2010 Aug 1;21(8):883-9. doi: 10.1111/j.1540-8167.2009.01716.x. Epub 2010 Feb 1.

PMID:
20132378
11.

Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy.

Almquist AK, Montgomery JV, Haas TS, Maron BJ.

Heart Rhythm. 2005 Aug;2(8):814-9.

PMID:
16051115
13.

Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator.

Primo J, Geelen P, Brugada J, Filho AL, Mont L, Wellens F, Valentino M, Brugada P.

J Am Coll Cardiol. 1998 Apr;31(5):1081-5.

14.

Predictors of appropriate implantable cardioverter-defibrillator therapy during long-term follow-up of patients with coronary artery disease.

Blumer J, Wolber T, Hellermann J, Holzmeister J, Binggeli C, Duru F, Brunckhorst C.

Int Heart J. 2009 May;50(3):313-21.

15.

Management of hypertrophic cardiomyopathy in children.

Seggewiss H, Rigopoulos A.

Paediatr Drugs. 2003;5(10):663-72. Review.

PMID:
14510624
16.

Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.

Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA.

Heart. 2009 May;95(9):709-14. doi: 10.1136/hrt.2008.150656. Epub 2009 Mar 11.

PMID:
19282314
17.

Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.

McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, Schaff HV, Tajik AJ, Gersh BJ.

Eur Heart J. 2007 Nov;28(21):2583-8. Epub 2007 May 4.

18.
19.

Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.

Maron BJ, Spirito P.

J Cardiovasc Electrophysiol. 2008 Oct;19(10):1118-26. doi: 10.1111/j.1540-8167.2008.01147.x. Epub 2008 Mar 31. Review.

PMID:
18384577
20.

Appropriate ICD therapy in patients with idiopathic dilated cardiomyopathy: long term follow-up.

Karaoguz R, Maydanozcu S, Altun T, Güldal M, Akyürek O, Erol C.

Int Heart J. 2006 Sep;47(5):763-73.

Items per page

Supplemental Content

Write to the Help Desk